Diffuse melanosis arising from metastatic melanoma: pathogenetic function of elevated melanocyte peptide growth factors

Journal of the American Academy of Dermatology
M BöhmD Metze

Abstract

The origin of diffuse melanosis resulting from metastatic melanoma is unknown. We examined the light microscopic and ultrastructural changes in the skin of an affected 35-year-old woman and determined the peripheral blood levels of melanocyte growth factors. A total of 7 biopsy specimens were examined by light and electron microscopy and immunohistology (S-100, HMB45, MART1, CD68, MAC387). Serum/plasma levels of melanocyte growth factors of the patient were determined by enzyme-linked immunosorbent assays and compared with those of normal volunteers (n = 10) and amelanotic patients with metastatic melanoma (n = 10), matched to the UICC stage of the affected patient. Hyperpigmented but otherwise apparently normal skin of the patient displayed epidermal melanocyte hyperplasia, increased melanogenesis, and dermal pigment stored in histiocytes and other cells along with extracellular deposits. Blood levels of alpha-melanocyte stimulating hormone, hepatocyte growth factor, and endothelin-1 were significantly elevated in the affected patient. Aberrant production of these factors may not only be responsible for activation of the pigment system in diffuse melanosis of metastatic melanoma, but also for increased proliferation, motility,...Continue Reading

References

Feb 1, 1989·Journal of the American Academy of Dermatology·M Sexton, C R Snyder
Dec 1, 1974·The British Journal of Dermatology·K Konrad, K Wolff
Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·Z Abdel-MalekV J Hearing
Aug 1, 1996·Journal of the American Academy of Dermatology·M V Klaus, F Shah
Mar 1, 1997·Immunology Today·J M Lipton, A Catania
Jun 20, 1998·The Journal of Biological Chemistry·M OkazawaT Masaki
Jun 2, 1998·The British Journal of Surgery·A ShankarI Taylor
Jan 5, 1999·Dermatology : International Journal for Clinical and Investigative Dermatology·K TsukamotoS Shimada
Mar 24, 2000·The British Journal of Dermatology·F WeberP Fritsch
Mar 1, 1954·The Journal of Investigative Dermatology·G T WILSON

❮ Previous
Next ❯

Citations

May 13, 2005·Photodermatology, Photoimmunology & Photomedicine·Andrew BurdVincent K M Poon
Jul 16, 2003·Journal of Cutaneous Pathology·Klaus J BusamWen-Jen Hwu
Feb 27, 2004·Journal of Cutaneous Pathology·Klaus J BusamPaul Chapman
Oct 4, 2007·International Journal of Dermatology·Arzu KiliçSeçil Soylu
Mar 22, 2013·International Journal of Surgical Pathology·Grettel León-MartínezCarlos Ortiz-Hidalgo
Jan 1, 2016·Annals of Dermatology·Joanna ManganaKarin Schad
Jun 25, 2008·American Journal of Clinical Dermatology·Thilo GambichlerAlexander Kreuter
May 27, 2010·Clinical and Experimental Dermatology·A PerezK Acland
Jun 1, 2010·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·M Böhm, T A Luger
Sep 2, 2019·BMJ Case Reports·Brian ChinaiSatyajeet Roy
Jan 31, 2016·Melanoma Research·Luis ChiribogaSumayah Jamal
Dec 25, 2010·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·C Hallermann, H-J Schulze

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis